GlassScriptPhysician profile
Royce R Syracuse
NPI 1134119605
$9,626.33
in general payments reported to CMS, 2019-2025
31 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $582 · 2021: $896 · 2022: $3,624 · 2023: $1,019 · 2024: $755 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,843.04 | 2019-2025 | Hydrus Microstent, Clareon Panoptix Pro, Clareon |
| Notal Vision, INC. | $1,385.39 | 2019-2024 | Foresee Home |
| US Retina LLC | $813.55 | 2019-2022 | |
| Allergan, INC. | $710.96 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $580.16 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $567.48 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $508.05 | 2019-2021 | |
| Abbvie INC. | $404.84 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $329.17 | 2019-2021 | |
| Horizon Therapeutics Plc | $249.98 | 2023 | Tepezza |
| Glaukos Corporation | $235.83 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.14 | 2022 | |
| Novo Nordisk INC | $219.92 | 2022 | |
| New World Medical,INC. | $218.75 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $188.93 | 2024-2025 | Xdemvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $128.22 | 2023 | Izervay |
| Paratek Pharmaceuticals, INC. | $124.99 | 2022 | |
| Amgen INC. | $121.16 | 2024 | Tepezza |
| Rxsight INC | $110.54 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Light Adjustable Lens (Rxlal) |
| Carl Zeiss Meditec Cataract Technology INC. | $105.03 | 2020 | |
| Biotissue Holdings INC. | $99.29 | 2021 | |
| Lilly USA, LLC | $97.49 | 2022 | |
| Oyster Point Pharma, INC. | $95.86 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $69.53 | 2019-2023 | Cequa, Xelpros |
| Rayner Intraocular Lenses Limited | $51.34 | 2025 | Omidria |
| Harrow Eye, LLC | $31.35 | 2025 | Vevye |
| Thea Pharma INC. | $28.55 | 2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.70 | 2021 | |
| Dompe US, INC. | $18.91 | 2025 | Oxervate |
| Eyepoint US, INC. | $17.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,869.91 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Royce Syracuse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.